iECURE to Present Clinical Data from Ongoing OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM Annual Symposium
Go back to iECURE to Present Clinical Data from Ongoing OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM Annual Symposium| (NASDAQ: DTIL) | Delayed: 6.67 +0.04 (0.60%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $6.63 | 52 Week High | $ | |||
| Open | $6.77 | 52 Week Low | $ | |||
| Day High | $6.92 | P/E | N/A | |||
| Day Low | $6.41 | EPS | $ | |||
| Volume | 373,895 | |||||

